MicroRNA as an Early Biomarker of Neonatal Sepsis

J 2022

MicroRNA as an Early Biomarker of Neonatal Sepsis

JOUZA, Martin, Júlia BOHOŠOVÁ, Andrea STANÍKOVÁ, Jakub PECL, Ondřej SLABÝ et. al.

Basic information

Original name

MicroRNA as an Early Biomarker of Neonatal Sepsis

Authors

JOUZA, Martin (203 Czech Republic, belonging to the institution), Júlia BOHOŠOVÁ (703 Slovakia, belonging to the institution), Andrea STANÍKOVÁ (703 Slovakia, belonging to the institution), Jakub PECL (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Petr JABANDŽIEV (203 Czech Republic, guarantor, belonging to the institution)

Edition

FRONTIERS IN PEDIATRICS, SWITZERLAND, FRONTIERS MEDIA SA, 2022, 2296-2360

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30209 Paediatrics

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.600

RIV identification code

RIV/00216224:14110/22:00126832

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3389/fped.2022.854324

UT WoS

000802241600001

Keywords in English

miRNA; inflammation; CRP; IL-6; sepsis

Abstract

V originále

Sepsis is a major cause of lethality in neonatal intensive care units. Despite significant advances in neonatal care and growing scientific knowledge about the disease, 4 of every 10 infants born in developed countries and suffering from sepsis die or experience considerable disability, including substantial and permanent neurodevelopmental impairment. Pharmacological treatment strategies for neonatal sepsis remain limited and mainly based upon early initiation of antibiotics and supportive treatment. In this context, numerous clinical and serum-based markers have been evaluated for diagnosing sepsis and evaluating its severity and etiology. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently, it was demonstrated in adult patients that miRNAs are released into the circulation and that the spectrum of circulating miRNAs is altered during various pathologic conditions, such as inflammation, infection, and sepsis. Here, we summarize current findings on the role of circulating miRNAs in the diagnosis and staging of neonatal sepsis. The conclusions point to substantial diagnostic potential, and several miRNAs have been validated independently by different teams, namely miR-16a, miR-16, miR-96-5p, miR-141, miR-181a, and miR-1184.

Citovat

JOUZA, Martin, Júlia BOHOŠOVÁ, Andrea STANÍKOVÁ, Jakub PECL, Ondřej SLABÝ and Petr JABANDŽIEV. MicroRNA as an Early Biomarker of Neonatal Sepsis. FRONTIERS IN PEDIATRICS. SWITZERLAND: FRONTIERS MEDIA SA, 2022, vol. 10, May 2022, p. 1-8. ISSN 2296-2360. Available from: https://dx.doi.org/10.3389/fped.2022.854324.

@article{2223178,
   author = {Jouza, Martin and Bohošová, Júlia and Staníková, Andrea and Pecl, Jakub and Slabý, Ondřej and Jabandžiev, Petr},
   article_location = {SWITZERLAND},
   article_number = {May 2022},
   doi = {http://dx.doi.org/10.3389/fped.2022.854324},
   keywords = {miRNA; inflammation; CRP; IL-6; sepsis},
   language = {eng},
   issn = {2296-2360},
   journal = {FRONTIERS IN PEDIATRICS},
   title = {MicroRNA as an Early Biomarker of Neonatal Sepsis},
   url = {https://www.frontiersin.org/articles/10.3389/fped.2022.854324/full},
   volume = {10},
   year = {2022}
}

TY  - JOUR
ID  - 2223178
AU  - Jouza, Martin - Bohošová, Júlia - Staníková, Andrea - Pecl, Jakub - Slabý, Ondřej - Jabandžiev, Petr
PY  - 2022
TI  - MicroRNA as an Early Biomarker of Neonatal Sepsis
JF  - FRONTIERS IN PEDIATRICS
VL  - 10
IS  - May 2022
SP  - 1-8
EP  - 1-8
PB  - FRONTIERS MEDIA SA
SN  - 22962360
KW  - miRNA
KW  - inflammation
KW  - CRP
KW  - IL-6
KW  - sepsis
UR  - https://www.frontiersin.org/articles/10.3389/fped.2022.854324/full
N2  - Sepsis is a major cause of lethality in neonatal intensive care units. Despite significant advances in neonatal care and growing scientific knowledge about the disease, 4 of every 10 infants born in developed countries and suffering from sepsis die or experience considerable disability, including substantial and permanent neurodevelopmental impairment. Pharmacological treatment strategies for neonatal sepsis remain limited and mainly based upon early initiation of antibiotics and supportive treatment. In this context, numerous clinical and serum-based markers have been evaluated for diagnosing sepsis and evaluating its severity and etiology. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently, it was demonstrated in adult patients that miRNAs are released into the circulation and that the spectrum of circulating miRNAs is altered during various pathologic conditions, such as inflammation, infection, and sepsis. Here, we summarize current findings on the role of circulating miRNAs in the diagnosis and staging of neonatal sepsis. The conclusions point to substantial diagnostic potential, and several miRNAs have been validated independently by different teams, namely miR-16a, miR-16, miR-96-5p, miR-141, miR-181a, and miR-1184.
ER  -

JOUZA, Martin, Júlia BOHOŠOVÁ, Andrea STANÍKOVÁ, Jakub PECL, Ondřej SLABÝ and Petr JABANDŽIEV. MicroRNA as an Early Biomarker of Neonatal Sepsis. \textit{FRONTIERS IN PEDIATRICS}. SWITZERLAND: FRONTIERS MEDIA SA, 2022, vol.~10, May 2022, p.~1-8. ISSN~2296-2360. Available from: https://dx.doi.org/10.3389/fped.2022.854324.

Detailed Information on Publication Record